Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments

References

• CotziasGCL-Dopa for ParkinsonismN Engl J Med1968278116305637779
   PubMed Web of Science ®Google Scholar
• AhlskogJEMuenterMDFrequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literatureMov Disord200116344845811391738
   PubMed Web of Science ®Google Scholar
• FahnSThe spectrum of levodopa-induced dyskinesiasAnn Neurol2000474 Suppl 1S2S9 discussion S9–S1110762127
   PubMed Web of Science ®Google Scholar
• ChapuisSOuchchaneLMetzOGerbaudLDurifFImpact of the motor complications of Parkinson’s disease on the quality of lifeMov Disord200520222423015384126
   PubMed Web of Science ®Google Scholar
• MaurelFLilliuHLe PenCSocial and economic cost of L-dopa-induced dyskinesias in patients with Parkinson’s diseaseRev Neurol (Paris)20011575507514 French11438770
   PubMed Web of Science ®Google Scholar
• CalabresiPDi FilippoMGhiglieriVTambascoNPicconiBLevodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gapLancet Neurol20109111106111720880751
   PubMed Web of Science ®Google Scholar
• PicconiBCentonzeDHåkanssonKLoss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesiaNat Neurosci20036550150612665799
   PubMed Web of Science ®Google Scholar
• GuigoniCDoveroSAubertILevodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioningEur J Neurosci200522128328716029219
   PubMed Web of Science ®Google Scholar
• LinazasoroGVan BlercomNBergaretxeAIñakiFMLabordaERuiz OrtegaJALevodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT studyClin Neuropharmacol200932632632919855268
   PubMed Web of Science ®Google Scholar
• Di MonteDAMcCormackAPetzingerGJansonAMQuikMLangstonWJRelationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate modelMov Disord200015345946610830409
   PubMed Web of Science ®Google Scholar
• PailléVBrachetPDamierPRole of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson’s diseaseNeuroreport200415356156415094523
   PubMed Web of Science ®Google Scholar
• de la Fuente-FernándezRDrug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuationsClin Neuropharmacol199922421621910442251
   PubMed Web of Science ®Google Scholar
• CenciMALundbladMPost- versus presynaptic plasticity in L-dopa-induced dyskinesiaJ Neurochem200699238139216942598
   PubMed Web of Science ®Google Scholar
• CartaMCarlssonTKirikDBjörklundADopamine released from 5-HT terminals is the cause of L-dopa-induced dyskinesia in parkinsonian ratsBrain2007130Pt 71819183317452372
   PubMed Web of Science ®Google Scholar
• BlandiniFArmenteroMTNew pharmacological avenues for the treatment of L-dopa-induced dyskinesias in Parkinson’s disease: targeting glutamate and adenosine receptorsExp Opin Investig Drugs2012212153168
   PubMed Web of Science ®Google Scholar
• KannariKYamatoHShenHTomiyamaMSudaTMatsunagaMActivation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-dopa in the striatum with nigrostriatal denervationJ Neurochem20017651346135311238719
   PubMed Web of Science ®Google Scholar
• AnnicADevosDSeguyDDujardinKDestéeADefebvreLContinuous dopaminergic stimulation by Duodopa in advanced Parkinson’s disease: efficacy and safetyRev Neurol (Paris)20091658–9718727 French19150100
   PubMed Web of Science ®Google Scholar
• DeuschlGSchade-BrittingerCKrackPA randomized trial of deep-brain stimulation for Parkinson’s diseaseN Engl J Med2006355989690816943402
   PubMed Web of Science ®Google Scholar
• SmithYRajuDNandaBPareJFGalvanAWichmannTThe thalamostriatal systems: anatomical and functional organization in normal and parkinsonian statesBrain Res Bull2009782–3606818805468
   PubMed Web of Science ®Google Scholar
• BlandiniFAn update on the potential role of excitotoxicity in the pathogenesis of Parkinson’s diseaseFunct Neurol2010252657120923603
   PubMed Web of Science ®Google Scholar
• HallettPJDunahAWRavenscroftPAlterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson’s diseaseNeuropharmacology200548450351615755478
   PubMed Web of Science ®Google Scholar
• GardoniFPicconiBGhiglieriVA critical interaction between NR2B and MAGUK in L-dopa induced dyskinesiaJ Neurosci200626112914292216540568
   PubMed Web of Science ®Google Scholar
• OhJDRussellDSVaughanCLChaseTNEnhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-dopa administrationBrain Res199881311501599824689
   PubMed Web of Science ®Google Scholar
• NapolitanoMPicconiBCentonzeDBernardiGCalabresiPGulinoAL-dopa treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinasesNeurosci Lett2006398321121416529858
   PubMed Web of Science ®Google Scholar
• BlanchetPJKonitsiotisSChaseTNAmantadine reduces levodopa-induced dyskinesias in parkinsonian monkeysMov Disord19981357988029756148
   PubMed Web of Science ®Google Scholar
• LundbladMUsielloACartaMHåkanssonKFisoneGCenciMAPharmacological validation of a mouse model of l-dopa-induced dyskinesiaExp Neurol20051941667515899244
   PubMed Web of Science ®Google Scholar
• MetmanLVDel DottoPLePooleKKonitsiotisSFangJChaseTNAmantadine for levodopa-induced dyskinesias: a 1-year follow-up studyArch Neurol199956111383138610555659
   PubMedGoogle Scholar
• LugingerEWenningGKBöschSPoeweWBeneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s diseaseMov Disord200015587387811009193
   PubMed Web of Science ®Google Scholar
• SnowBJMacdonaldLMcAuleyDWallisWThe effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled studyClin Neuropharmacol2000232828510803797
   PubMed Web of Science ®Google Scholar
• Del DottoPPaveseNGambacciniGIntravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled studyMov Disord200116351552011391748
   PubMed Web of Science ®Google Scholar
• ThomasAIaconoDLucianoALArmellinoKDi IorioAOnofrjMDuration of amantadine benefit on dyskinesia of severe Parkinson’s diseaseJ Neurol Neurosurg Psychiatry200475114114314707325
   PubMed Web of Science ®Google Scholar
• WolfESeppiKKatzenschlagerRLong-term antidyskinetic efficacy of amantadine in Parkinson’s diseaseMov Disord201025101357136320198649
   PubMed Web of Science ®Google Scholar
• JahangirvandARajputAEarly use of amantadine to prevent or delay onset of levodopainduced dyskinesia in Parkinson’s diseaseMov Disord201328Suppl 1S207
   Google Scholar
• PahwaRTannerCMHauserRARandomized trial of extended release amantadine in Parkinson’s disease patients with levodopa-induced dyskinesia (EASED study)Mov Disord201328Suppl 1S158
   Google Scholar
• Parkinson Study GroupEvaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson diseaseArch Neurol200158101660166811594926
   PubMedGoogle Scholar
• Bara-JimenezWDimitrovaTDSherzaiAAksuMChaseTNGlutamate release inhibition ineffective in levodopa-induced motor complicationsMov Disord20062191380138316758479
   PubMed Web of Science ®Google Scholar
• Verhagen MetmanLDel DottoPNatteRvan den MunckhofPChaseTNDextromethorphan improves levodopa-induced dyskinesias in Parkinson’s diseaseNeurology19985112032069674803
   PubMed Web of Science ®Google Scholar
• ZhangYBrittoMRValderhaugKLWedlundPJSmithRADextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6Clin Pharmacol Ther19925166476551611804
   PubMed Web of Science ®Google Scholar
• Avanir PharmaceuticalsSafety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson’s Disease Patients (LID in PD)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2013 [updated July 29, 2013]. Available from: http://clinicaltrials.gov/show/NCT01767129. NLM identifier: NCT01767129Accessed September 6, 2013
   Google Scholar
• MerelloMNouzeillesMICammarotaALeiguardaREffect of memantine (NMDA antagonist) on Parkinson’s disease: a double-blind crossover randomized studyClin Neuropharmacol199922527327610516877
   PubMed Web of Science ®Google Scholar
• MoreauCDelvalATiffreauVMemantine for axial signs in Parkinson’s disease: a randomised, double-blind, placebo-controlled pilot studyJ Neurol Neurosurg Psychiatry201384555255523077087
   PubMed Web of Science ®Google Scholar
• VaraneseSHowardJDi RoccoANMDA antagonist memantine improves levodopa-induced dyskinesias and “on-off” phenomena in Parkinson’s diseaseMov Disord201025450851020014061
   PubMed Web of Science ®Google Scholar
• VidalEIFukushimaFBValleAPVillas BoasPJUnexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson’s disease dementiaJ Am Geriatr Soc201361117017223311565
   PubMed Web of Science ®Google Scholar
• WessellRHAhmedSMMennitiFSDunbarGLChaseTNOhJDNR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian ratsNeuropharmacology200447218419415223297
   PubMed Web of Science ®Google Scholar
• NashJERavenscroftPMcGuireSCrossmanARMennitiFSBrotchieJMThe NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-dopa-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-dopa in the MPTP-lesioned marmoset model of Parkinson’s diseaseExp Neurol2004188247147915246846
   PubMed Web of Science ®Google Scholar
• NuttJGGunzlerSAKirchhoffTEffects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and ParkinsonismMov Disord200823131860186618759356
   PubMed Web of Science ®Google Scholar
• Neurim Pharmaceuticals LtdSafety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced DyskinesiaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2008 [updated June 9, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00607451?term=NCT00607451&rank=1. NLM identifier: NCT00607451Accessed September 6, 2013
   Google Scholar
• PicconiBPisaniACentonzeDStriatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatmentBrain2002125Pt 122635264512429591
   PubMed Web of Science ®Google Scholar
• SamadiPRajputACalonFMetabotropic glutamate receptor II in the brains of Parkinsonian patientsJ Neuropathol Exp Neurol200968437438219287314
   PubMed Web of Science ®Google Scholar
• MasilamoniGJBogenpohlJWAlagilleDMetabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeysBrain2011134Pt 72057207321705423
   PubMed Web of Science ®Google Scholar
• VernonACPalmerSDatlaKPZbarskyVCroucherMJDexterDTNeuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson’s diseaseEur J Neurosci20052271799180616197521
   PubMed Web of Science ®Google Scholar
• MelaFMartiMDekundyADanyszWMorariMCenciMAAntagonism of metabotropic glutamate receptor type 5 attenuates l-dopa-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s diseaseJ Neurochem2007101248349717359492
   PubMed Web of Science ®Google Scholar
• RylanderDRecchiaAMelaFDekundyADanyszWCenciMAPharmacological modulation of glutamate transmission in a rat model of L-dopa-induced dyskinesia: effects on motor behavior and striatal nuclear signalingJ Pharmacol Exp Ther2009330122723519357321
   PubMed Web of Science ®Google Scholar
• JohnstonTHFoxSHMcIldowieMJPiggottMJBrotchieJMReduction of L-dopa-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl] pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson’s diseaseJ Pharmacol Exp Ther2010333386587320231306
   PubMed Web of Science ®Google Scholar
• LevandisGBazziniEArmenteroMTNappiGBlandiniFSystemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-dopa-induced dyskinesias in a rodent model of Parkinson’s diseaseNeurobiol Dis200829116116817933546
   PubMed Web of Science ®Google Scholar
• DekundyAPietraszekMSchaeferDCenciMADanyszWEffects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson’s diseaseBrain Res Bull200669331832616564428
   PubMed Web of Science ®Google Scholar
• GrégoireLMorinNOuattaraBThe acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-dopa-treated parkinsonian monkeysParkinsonism Relat Disord201117427027621315648
   PubMed Web of Science ®Google Scholar
• BergDGodauJTrenkwalderCAFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trialsMov Disord20112671243125021484867
   PubMed Web of Science ®Google Scholar
• StocchiFRascolODesteeAAFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding studyMov Disord EpubJuly122013
   Web of Science ®Google Scholar
• Novartis PharmaceuticalsOpen Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson’s Patients With L-dopa Induced DyskinesiasClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated December 6, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01173731?term=NCT01173731&rank=1. NLM identifier: NCT01173731Accessed September 6, 2013
   Google Scholar
• TisonFDurifFChristopheJSafety, tolerability and anti-dyskinetic efficacy of dipraglurant, a novel mGluR5 negative allosteric modulator (NAM) in Parkinson’s disease (PD) patients with levodopa-induced dyskinesiaPoster presented at: 65th American Academy of Neurology Annual MeetingMarch 16–23, 2013San Diego, CA, USA
   Google Scholar
• KonitsiotisSBlanchetPJVerhagenLLamersEChaseTNAMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeysNeurology20005481589159510762498
   PubMed Web of Science ®Google Scholar
• National Institute of Neurological Disorders and Stroke (NINDS)Talampanel to Treat Parkinson’s DiseaseClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2005 [updated March 3, 2008]. Available from: http://clinicaltrials.gov/ct2/show/NCT00108667?term=NCT00108667&rank=1. NLM identifier: NCT00108667Accessed September 6, 2013
   Google Scholar
• Teva Pharmaceutical IndustriesEffects of Talampanel on Patients With Advanced Parkinson’s DiseaseClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2002 [updated April 11, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00036296?term=NCT00036296&rank=1Accessed September 6, 2013
   Google Scholar
• National Institute of Neurological Disorders and Stroke (NINDS)Study of LY300164 for the Treatment of Parkinson’s DiseaseClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2000 [updated March 3, 2008]. Available from: http://clinicaltrials.gov/ct2/show/NCT00004576?term=NCT00004576&rank=1Accessed September 6, 2013
   Google Scholar
• EggertKSquillacoteDBaronePSafety and efficacy of perampanel in advanced Parkinson’s disease: a randomized, placebo-controlled studyMov Disord201025789690520461807
   PubMed Web of Science ®Google Scholar
• LeesAFahnSEggertKMPerampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson’s diseaseMov Disord201227228428822161845
   PubMed Web of Science ®Google Scholar
• RascolOBaronePBehariMPerampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacaponeClin Neuropharmacol2012351152022222634
   PubMed Web of Science ®Google Scholar
• SavolaJMHillMEngstromMFipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson’s diseaseMov Disord200318887288312889076
   PubMed Web of Science ®Google Scholar
• HenryBFoxSHPeggsDCrossmanARBrotchieJMThe alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson’s diseaseMov Disord199914574475310495035
   PubMed Web of Science ®Google Scholar
• GrondinRHadj TaharADoanVDLadurePBedardPJNoradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeysNaunyn Schmiedebergs Arch Pharmacol2000361218118610685874
   PubMed Web of Science ®Google Scholar
• RascolOArnulfIPeyro-Saint PaulHIdazoxan, an alpha-2 antagonist, and L-dopa-induced dyskinesias in patients with Parkinson’s diseaseMov Disord200116470871311481696
   PubMed Web of Science ®Google Scholar
• MansonAJIakovidouELeesAJIdazoxan is ineffective for levodopa-induced dyskinesias in Parkinson’s diseaseMov Disord200015233633710752589
   PubMed Web of Science ®Google Scholar
• LewittPAHauserRALuMRandomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)Neurology201279216316922744665
   PubMed Web of Science ®Google Scholar
• Valeant Pharmaceuticals International, IncA Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson’s Disease Who Are Receiving LevodopaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated August 30, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01140841?term=NCT01140841&rank=1. NLM identifier: NCT01140841Accessed September 6, 2013
   Google Scholar
• Valeant Pharmaceuticals International, IncA Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson’s DiseaseClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated June 20, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01149811?term=NCT01149811&rank=1. NLM identifier: NCT01149811Accessed September 6, 2013
   Google Scholar
• HickeyPStacyMAdenosine A2A antagonists in Parkinson’s disease: what’s next?Curr Neurol Neurosci Rep201212437638522585137
   PubMed Web of Science ®Google Scholar
• MoriAShindouTModulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonistsNeurology20036111 Suppl 6S44S4814663009
   PubMedGoogle Scholar
• MorelliMDi PaoloTWardasJCalonFXiaoDSchwarzschildMARole of adenosine A2A receptors in parkinsonian motor impairment and l-dopa-induced motor complicationsProg Neurobiol200783529330917826884
   PubMed Web of Science ®Google Scholar
• CalonFDridiMHornykiewiczOBedardPJRajputAHDi PaoloTIncreased adenosine A2A receptors in the brain of Parkinson’s disease patients with dyskinesiasBrain2004127Pt 51075108415033896
   PubMed Web of Science ®Google Scholar
• CartaARPinnaACauliOMorelliMDifferential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated ratsSynapse200244316617411954048
   PubMed Web of Science ®Google Scholar
• HodgsonRABertorelliRVartyGBCharacterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4–2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depressionJ Pharmacol Exp Ther2009330129430319332567
   PubMed Web of Science ®Google Scholar
• HodgsonRABedardPJVartyGBPreladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disordersExp Neurol2010225238439020655910
   PubMed Web of Science ®Google Scholar
• HauserRACantillonMPourcherEPreladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trialLancet Neurol201110322122921315654
   PubMed Web of Science ®Google Scholar
• FactorSAWolskiKTogasakiDMLong-term safety and efficacy of preladenant in subjects with fluctuating Parkinson’s diseaseMov Disord201328681782023589371
   PubMed Web of Science ®Google Scholar
• HauserRAShulmanLMTrugmanJMStudy of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuationsMov Disord200823152177218518831530
   PubMed Web of Science ®Google Scholar
• LeWittPAGuttmanMTetrudJWAdenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)Ann Neurol200863329530218306243
   PubMed Web of Science ®Google Scholar
• PourcherEFernandezHHStacyMMoriABalleriniRChaikinPIstradefylline for Parkinson’s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 studyParkinsonism Relat Disord201218217818422000279
   PubMed Web of Science ®Google Scholar
• MizunoYHasegawaKKondoTKunoSYamamotoMClinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled studyMov Disord201025101437144320629136
   PubMed Web of Science ®Google Scholar
• Bara-JimenezWSherzaiADimitrovaTAdenosine A(2A) receptor antagonist treatment of Parkinson’s diseaseNeurology200361329329612913186
   PubMed Web of Science ®Google Scholar
• HauserRAOlanowCWKieburtzKA phase 2, placebo-controlled, randomized, double-blind trial of tozadenant (SYN-115) in patients with Parkinson’s disease with wearing-off fluctuations on levodopaMov Disord201328Suppl 1S158
   Google Scholar
• WonnacottSPresynaptic nicotinic ACh receptorsTrends Neurosci199720292989023878
   PubMed Web of Science ®Google Scholar
• ZhouFMLiangYDaniJAEndogenous nicotinic cholinergic activity regulates dopamine release in the striatumNat Neurosci20014121224122911713470
   PubMed Web of Science ®Google Scholar
• BordiaTCamposCHuangLQuikMContinuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-dopa)-induced dyskinesias in a rat model of Parkinson’s diseaseJ Pharmacol Exp Ther2008327123924718650244
   PubMed Web of Science ®Google Scholar
• QuikMCoxHParameswaranNO’LearyKLangstonJWDi MonteDNicotine reduces levodopa-induced dyskinesias in lesioned monkeysAnn Neurol200762658859617960553
   PubMed Web of Science ®Google Scholar
• QuikMMallelaAChinMMcIntoshJMPerezXABordiaTNicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal functionNeurobiol Dis201350304123009753
   PubMed Web of Science ®Google Scholar
• QuikMMallelaALyJZhangDNicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson’s diseaseMov Disord EpubJuly82013
   Web of Science ®Google Scholar
• LemaySChouinardSBlanchetPLack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson’s diseaseProg Neuropsychopharmacol Biol Psychiatry2004281313914687854
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupRandomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson diseaseNeurology200666340841016476941
   PubMed Web of Science ®Google Scholar
• VillafaneGCesaroPRiallandAChronic high dose transdermal nicotine in Parkinson’s disease: an open trialEur J Neurol200714121313131617941858
   PubMed Web of Science ®Google Scholar
• ViereggeASiebererMJacobsHHagenahJMViereggePTransdermal nicotine in PD: a randomized, double-blind, placebo-controlled studyNeurology20015761032103511571330
   PubMed Web of Science ®Google Scholar
• Neuraltus Pharmaceuticals IncStudy of NP002 in Subjects With Idiopathic Parkinson’s Disease to Treat Dyskinesias Due to Levodopa TherapyClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2009 [updated September 26, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00957918?term=NCT00957918&rank=1. NLM identifier: NCT00957918Accessed September 6, 2013
   Google Scholar
• BordiaTCamposCMcIntoshJMQuikMNicotinic receptor-mediated reduction in L-dopa-induced dyskinesias may occur via desensitizationJ Pharmacol Exp Ther2010333392993820200117
   PubMed Web of Science ®Google Scholar
• HuangLZCamposCLyJIvy CarrollFQuikMNicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian ratsNeuropharmacology201160686186821232546
   PubMed Web of Science ®Google Scholar
• MecoGStirpePEditoFAripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot studyJ Neural Transm2009116788188419533295
   PubMed Web of Science ®Google Scholar
• Tayarani-BinazirKJacksonMJRoseSMcCrearyACJennerPThe partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosetsExp Neurol2010226232032720843474
   PubMed Web of Science ®Google Scholar
• BronzovaJSampaioCHauserRADouble-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s diseaseMov Disord201025673874620198713
   PubMed Web of Science ®Google Scholar
• RascolOBronzovaJHauserRAPardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trialParkinsonism Relat Disord201218437037622316635
   PubMed Web of Science ®Google Scholar
• HauserRABronzovaJSampaioCSafety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson’s diseaseEur Neurol2009621404819407454
   PubMed Web of Science ®Google Scholar
• Ligand PharmaceuticalsThe Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson’s DiseaseClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2008 [updated September 29, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00623324?term=NCT00623324&rank=1. NLM identifier: NCT00623324Accessed September 6, 2013
   Google Scholar
• WatersCHSethiKDHauserRAMolhoEBertoniJMZydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled studyMov Disord200419442643215077240
   PubMed Web of Science ®Google Scholar
• RascolOBrooksDJMelamedERasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting Effect in Adjunct Therapy with Rasagiline Given Once Daily, study): a randomised, double-blind, parallel-group trialLancet2005365946394795415766996
   PubMed Web of Science ®Google Scholar
• GrégoireLJourdainVATownsendMRoachADi PaoloTSafinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeysParkinsonism Relat Disord201319550851423402994
   PubMed Web of Science ®Google Scholar
• BorgohainRSzaszJStanzionePFirst 2-year, controlled study to assess safinamide as add-on to levodopa in Parkinson’s disease with motor fluctuationsMov Disord201126Suppl 2S120
   Google Scholar
• ShoulsonIOakesDFahnSImpact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trialAnn Neurol200251560461212112107
   PubMed Web of Science ®Google Scholar
• TalatiRReinhartKBakerWWhiteCMColemanCIPharmacologic treatment of advanced Parkinson’s disease: a meta-analysis of COMT inhibitors and MAO-B inhibitorsParkinsonism Relat Disord200915750050519167259
   PubMed Web of Science ®Google Scholar
• TomiyamaMKimuraTMaedaTKannariKMatsunagaMBabaMA serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-dopa in a rodent model of Parkinson’s diseaseNeurosci Res200552218519415893579
   PubMed Web of Science ®Google Scholar
• KannariKKurahashiKTomiyamaMTandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson’s diseaseNo To Shinkei200254213313711889759
   PubMedGoogle Scholar
• OlanowCWDamierPGoetzCGMulticenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)Clin Neuropharmacol2004272586215252265
   PubMed Web of Science ®Google Scholar
• GoetzCGLaskaEHickingCPlacebo influences on dyskinesia in Parkinson’s diseaseMov Disord200823570070718175337
   PubMed Web of Science ®Google Scholar
• RascolODamierPGoetzCGA large phase III study to evaluate the safety and efficacy of sarizotan in the treatment of L-dopa-induced dyskinesia associated with Parkinson’s disease: the Paddy-1 studyMov Disord200621Suppl 15S492S493
   Google Scholar
• MüllerTOlanowCWNuttJThe PADDY-2 study: the evaluation of sarizotan for treatment-associated dyskinesia in Parkinson’s disease patientsMov Disord200621Suppl 15S591
   Google Scholar
• Asubio Pharmaceuticals IncPreliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson’s DiseaseClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2008 [updated April 4, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00623363?term=NCT00623363&rank=1. NLM identifier: NCT00623363Accessed September 6, 2013
   Google Scholar
• BezardETronciEPioliEYStudy of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesiaMov Disord20132881088109623389842
   PubMed Web of Science ®Google Scholar
• NeuroSearch initiates a clinical study with ACR325 for the treatment of dyskinesias (involuntary movements) in Parkinson’s disease [webpage on the Internet]CopenhagenNeuroSearch A/S2009 Available from https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=368187&messageId=439581Accessed September 26, 2013
   Google Scholar
• PricePAParkesJDMarsdenCDSodium valproate in the treatment of levodopa-induced dyskinesiaJ Neurol Neurosurg Psychiatry1978418702706355601
   PubMed Web of Science ®Google Scholar
• Van BlercomNLasaAVergerKMasramonXSastreVMLinazasoroGEffects of gabapentin on the motor response to levodopa: a double-blind, placebo-controlled, crossover study in patients with complicated Parkinson diseaseClin Neuropharmacol200427312412815190235
   PubMed Web of Science ®Google Scholar
• MurataMHasegawaKKanazawaIZonisamide improves motor function in Parkinson disease: a randomized, double-blind studyNeurology2007681455017200492
   PubMed Web of Science ®Google Scholar
• WongKKAltyJEGoyAGRaghavSReutensDCKempsterPAA randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson’s diseaseMov Disord20112681552155521538524
   PubMed Web of Science ®Google Scholar
• StathisPKonitsiotisSTagarisGPetersonDLevetiracetam for the management of levodopa-induced dyskinesias in Parkinson’s diseaseMov Disord201126226427021412833
   PubMed Web of Science ®Google Scholar
• WolzMLohleMStreckerKLevetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trialJ Neural Transm2010117111279128620803300
   PubMed Web of Science ®Google Scholar
• University Health Network, TorontoTopiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson’s DiseaseClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2006 [updated September 19, 2007]. Available from: http://clinicaltrials.gov/ct2/show/NCT00296959?term=NCT00296959&rank=1. NLM identifier: NCT00296959Accessed September 6, 2013
   Google Scholar
• NeuroSearch A/SSafety and Tolerability Study Evaluating ACR325 in Parkinson’s Disease PatientsClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2009 [updated November 1, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01023282?term=NCT01023282&rank=1. NLM identifier: NCT01023282Accessed September 6, 2013
   Google Scholar
• HuotPBrotchieJM5-HT(1A) receptor stimulation and L-dopa-induced dyskinesia in Parkinson’s disease: bridging the gap between serotonergic and glutamatergic mechanismsExp Neurol2011231219519821819982
   PubMed Web of Science ®Google Scholar
• HuotPJohnstonTHKoprichJBFoxSHBrotchieJMThe pharmacology of L-dopa-induced dyskinesia in Parkinson’s diseasePharmacol Rev201365117122223319549
   PubMed Web of Science ®Google Scholar